iifl-logo-icon 1
IIFL

Invest wise with Expert advice

By continuing, I accept the T&C and agree to receive communication on Whatsapp

  • Open Demat with exclusive Advice & Services
  • Get a dedicated Relationship Manager to help you grow your wealth
  • Exclusive advisory on 20+ trading & wealth-based investment options
  • One tap Investments, Automated trading & much more
  • Minimum 1 lakh margin required
sidebar image

Q3FY24 Review: Cipla: Advair/Abraxane delay partly offset by Peptides

29 Jan 2024 , 12:37 PM

Cipla’s Q3 Ebitda was 10% ahead of analysts of IIFL Securities estimates, driven by a 3yr high GM performance, on the back of higher chronic revenue share in the India business, price hikes in India portfolio, and base business growth in the US. While Q3 performance was strong, analysts of IIFL Securities expect the usual Q4 seasonality in the India and US businesses will probably lead to Ebitda margins declining from ~25% in M9FY24 to ~21% in Q4FY24. Although Abraxane and Advair launches in the US will likely get delayed to FY26 now, Cipla intends to partly offset this impact through launches of 4 peptide assets in FY25, out of which 2 peptide launches are contingent on settlement of litigation. Symbicort launch will likely be in FY27 only, as the product will take two years to receive USFDA approval. With the stock trading at ~26x FY26 core EPS (ex-Revlimid), analysts of IIFL Securities believe most of the positives (double-digit growth in India, robust US pipeline for FY26/27) are already priced-in. They upgrade FY25/26 EPS by 2- 4%, to account for higher margins and lower D&A. Maintain ADD. 

Advair and Abraxane launches in the US will likely get delayed to FY26 now: 

Advair alternate-site filing is expected in mid-FY25, post which USFDA will take 6-9 months to approve the product. Also, Cipla will look to launch Abraxane through the Goa plant only as alternate-site filing would have needed additional clinical trials to be done. However, Abraxane approval will be contingent on Goa re-inspection (earliest by Q1FY25) and clearance. Analysts of IIFL Securities now assume Advair/Abraxane launch only in Q1FY26 (vs Q3FY25 earlier), with sales contribution of USD50/35m resp. in FY26. 

Analysts of IIFL Securities analysis of Cipla’s peptide pipeline shows that it has generic versions of Vasostrict, Forteo and Saxenda, with Orbicular being the partner for some of the peptides. However, Vasostrict has already gone generic, while Teva is the FTF for both Forteo and Saxenda. Cipla is targeting 4 peptide launches in FY25, out of which 2 are just dependent on USFDA approval and the other 2 will be contingent on litigation. Each peptide product can potentially contribute USD10-40m revenue to Cipla. 

Analysts of IIFL Securities expect Cipla’s US sales to increase from USD910mn in FY24 to USD980mn in FY25, as peptide launches will be the only key triggers in FY25. Advair, Abraxane and Symbicort launches will likely lead to US sales increasing to USD1.15bn in FY26/27. Led by robust US launches and 10% growth in the India portfolio, analysts of IIFL Securities forecast Cipla’s core EPS (ex-Revlimid) to clock 14% Cagr over FY24-27.

Related Tags

  • Cipla
sidebar mobile

BLOGS AND PERSONAL FINANCE

Read More
Knowledge Centerplus
Logo

Logo IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000

Logo IIFL Securities Support WhatsApp Number
+91 9892691696

Download The App Now

appapp
Knowledge Centerplus

Follow us on

facebooktwitterrssyoutubeinstagramlinkedin

2024, IIFL Securities Ltd. All Rights Reserved

ATTENTION INVESTORS
  • Prevent Unauthorized Transactions in your demat / trading account Update your Mobile Number/ email Id with your stock broker / Depository Participant. Receive information of your transactions directly from Exchanges on your mobile / email at the end of day and alerts on your registered mobile for all debits and other important transactions in your demat account directly from NSDL/ CDSL on the same day." - Issued in the interest of investors.
  • KYC is one time exercise while dealing in securities markets - once KYC is done through a SEBI registered intermediary (broker, DP, Mutual Fund etc.), you need not undergo the same process again when you approach another intermediary.
  • No need to issue cheques by investors while subscribing to IPO. Just write the bank account number and sign in the application form to authorise your bank to make payment in case of allotment. No worries for refund as the money remains in investor's account."

www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.

RISK DISCLOSURE ON DERIVATIVES
  • 9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
  • On an average, loss makers registered net trading loss close to Rs. 50,000.
  • Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
  • Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.
Copyright © IIFL Securities Ltd. All rights Reserved.

Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248

plus
We are ISO 27001:2013 Certified.

This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.